GLAUKOS Corp (GKOS)

Glaukos reported third-quarter adjusted earnings of $0.47 per share, well ahead of the $(0.09) consensus, while revenue of $211.030 million beat the $168.048 million forecast. The company also lifted its fiscal 2026 sales outlook to $775 million-$785 million from a prior $680 million-$700 million range, above the $691.624 million consensus, and issued a fiscal 2027 sales outlook of $1.000 billion versus the $852.440 million estimate. Despite the bullish news, the stock closed slightly lower at $181.43, down 0.28% from the open of $181.94, after trading between a low of $174.75 and a high of $187.94 on volume of 1,557,582. The strong earnings beat and raised guidance signal positive momentum, though the muted price reaction suggests the market may have already priced in some optimism.

Glaukos shares rose 3.52% to close at $165.69 on heavy volume of 1,188,401 shares, driven by two positive clinical announcements. The company revealed superior intraocular pressure reduction with a novel eye therapy and reported topline results from its Phase 4 trial evaluating iDose TR with cataract surgery, which met its primary efficacy endpoint by demonstrating statistically significant and clinically meaningful IOP reduction versus cataract surgery alone. These bullish product and trial updates likely fueled the stock's move toward its intraday high of $166.97. The news signals continued momentum in Glaukos's pipeline and supports a positive direction for the stock.

Glaukos (GKOS) shares fell 5.50% today, closing at $161.29 after opening at $170.67 and trading as low as $146.38 on heavy volume of 2.88 million shares. The decline came despite two bullish announcements: the company reported three-year Epioxa trial data and entered an exclusive licensing agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a novel tri-specific biologic. The positive news failed to lift the stock, suggesting broader market pressures or profit-taking may have outweighed the product and contract catalysts. Given the strong intraday recovery from the $146.38 low, the direction signal remains UP based on the underlying news.